# Sildenafil to Increase Exercise Capacity in Individuals With Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension

> **NCT00352482** · PHASE2 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 20 (estimated)

## Conditions studied

- Pulmonary Fibrosis
- Hypertension, Pulmonary

## Interventions

- **DRUG:** Sildenafil (50 mg)

## Key facts

- **NCT ID:** NCT00352482
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** —
- **Final completion:** 2007-07
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2016-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00352482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00352482, "Sildenafil to Increase Exercise Capacity in Individuals With Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00352482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*